AR-R17779

Из Википедије, слободне енциклопедије
AR-R17779
AR-R17779 structure.png
Nazivi
IUPAC naziv
(2S)-2′H-spiro[4-azabiciklo[2.2.2]oktan-2,5'-[1,3]oksazolidin]-2'-on
Identifikacija
3D model (Jmol)
ChEBI
ChemSpider
Svojstva
C9H14N2O2
Molarna masa 182,22 g·mol−1
Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa).
ДаY verifikuj (šta je ДаYНеН ?)
Reference infokutije

AR-R17779 je lek koji deluje kao potentan i selektivan pun agonist za α7 podtip neurskih nikotinskih acetilholinskih receptora.[3][4] On ispoljava nootropne efekte u životinjskim studijama,[5][6] mada ta dejstva ne zamenjuju dejstva nikotina.[7] On je nedavno izučavan kao potentan nov tretman za artritis.[8]

Reference[уреди]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.  edit
  2. Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1. 
  3. Mullen, G.; Napier, A.; Balestra, M.; Decory, T.; Hale, G.; Macor, J.; Mack, R.; Loch J, J.; Wu, E. (2000). „(-)-Spiro1-azabicyclo2.2.2octane-3,5'-oxazolidin-2'-one, a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the alpha 7 nicotinic acetylcholine receptor”. Journal of Medicinal Chemistry. 43 (22): 4045—4050. PMID 11063601. doi:10.1021/jm000249r. 
  4. Macor, J. .; Mullen, G. .; Verhoest, P. .; Sampognaro, A. .; Shepardson, B. .; Mack, R. . (2004). „A chiral synthesis of (-)-spiro1-azabicyclo2.2.2octane-3,5'- oxazolidin-2'-one: a conformationally restricted analogue of acetylcholine that is a potent and selective alpha7 nicotinic receptor agonist”. The Journal of Organic Chemistry. 69 (19): 6493—6495. PMID 15357617. doi:10.1021/jo049404q. 
  5. Levin, E. D.; Bettegowda, C.; Blosser, J.; Gordon, J. (1999). „AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats”. Behavioural Pharmacology. 10 (6–7): 675—680. PMID 10780509. doi:10.1097/00008877-199911000-00014. 
  6. Van Kampen, M.; Selbach, K.; Schneider, R.; Schiegel, E.; Boess, F.; Schreiber, R. (2004). „AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors”. Psychopharmacology. 172 (4): 375—383. PMID 14727003. doi:10.1007/s00213-003-1668-7. 
  7. Grottick, A. J.; Trube, G.; Corrigall, W. A.; Huwyler, J.; Malherbe, P.; Wyler, R.; Higgins, G. A. (2000). „Evidence that nicotinic alpha(7) receptors are not involved in the hyperlocomotor and rewarding effects of nicotine”. The Journal of Pharmacology and Experimental Therapeutics. 294 (3): 1112—1119. PMID 10945867. 
  8. Van Maanen, M.; Lebre, M.; Van Der Poll, T.; Larosa, G.; Elbaum, D.; Vervoordeldonk, M.; Tak, P. (2009). „Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice”. Arthritis and rheumatism. 60 (1): 114—122. PMID 19116908. doi:10.1002/art.24177. 

Spoljašnje veze[уреди]